SALT LAKE CITY, Utah, Oct. 22, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), a leader in advanced silicon nitride biomaterials and ceramics for medical and industrial applications, today announced that it will release its third quarter 2026 financial results on Thursday, November 5, 2026, after the market close. The Company will also host a conference call and webcast that day at 4:30 p.m. ET to review the Company’s third quarter 2026 performance. Management participants will include Eric Olson, Chief Executive Officer and Chairman of the Board, and Kevin Trask, Chief Financial Officer.
Interested parties may access the conference call and webcast as follows:
Webcast: The live webcast will be available on the Events & Presentations page of the Company’s investor relations website at investors.sintx.com and may also be accessed directly here.
Telephone: Analysts and other participants who wish to join by telephone should register in advance using the Conference Call Registration link. Upon registration, participants will receive the dial-in information and a unique PIN.
A replay of the webcast will be available following the call on the Events & Presentations page of the Company’s investor relations website.
For more information on SINTX Technologies or its biomaterial platforms, visit www.sintx.com.
About SINTX Technologies, Inc.
Headquartered in Salt Lake City, Utah, SINTX Technologies, Inc. (NASDAQ: SINT) is an advanced biomaterials company that develops, manufactures, and commercializes patented and proprietary silicon nitride ceramic biomaterials, composites, devices, and related ceramics technologies for other medical and specialized industrial applications. SINTX has 20 years of experience innovating silicon nitride technologies and operates under a quality management system certified to ISO 13485:2016 and AS9100D, with a product portfolio that includes insulators for Tier 1 aerospace suppliers, the FDA-cleared SiNAPTIC® Foot & Ankle Osteotomy Wedge System for reconstructive surgery, OEM manufacturing of FDA-cleared spinal implants, and its SiNERGY™ technology platform being developed for biocomposite and 3D printing applications.
Company Contact:
Andrew Benson
SINTX Technologies, Inc.
801.839.3500
IR@sintx.com
